- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00432263
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.
April 21, 2015 updated by: Pfizer
Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement in patients with severe growth hormone deficiency after traumatic brain injury on cognitive function.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have had a previous traumatic brain injury (more than 1 year and less than 5 years) prior to the screening visit.
- Have an Extended Glasgow Outcome Scale (GOS-E) more than or equal to 5.
Exclusion Criteria:
- Active systemic malignancy or active intracranial tumor. A successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers.
- Receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. Topical and inhaled corticosteroids are permitted.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary endpoint is the change from baseline in the CogState™ composite score at Week 36.
|
Secondary Outcome Measures
Outcome Measure |
---|
Change CogState™ at Week 12, 24, 60 and 72. Change in lean body mass and fat mass at Week 36 and 72. Change in the Extended Glasgow Outcome Scale at week 36 and 72. Change in quality of life at week 24, 36, 60 and 72. Summary of change in cardiovascular
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Study Registration Dates
First Submitted
February 5, 2007
First Submitted That Met QC Criteria
February 6, 2007
First Posted (Estimate)
February 7, 2007
Study Record Updates
Last Update Posted (Estimate)
April 22, 2015
Last Update Submitted That Met QC Criteria
April 21, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A6281274
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Injuries
-
Eunice Kennedy Shriver National Institute of Child...CompletedTraumatic Brain Injuries
-
Technical University of MunichFederal Ministry of Defence (Germany); Bundesministerium der VerteidigungRecruitingTraumatic Brain InjuriesFrance, Germany
-
University of Colorado, DenverBinghamton University; Brooke Army Medical CenterRecruitingBrain ConcussionUnited States
-
University of Alabama at BirminghamCompletedTraumatic Brain InjuriesUnited States
-
Mosaic Life CareMissouri Western State UniversityTerminatedBrain Injuries | Brain Concussion | Athletic Injuries | Diffuse Axonal Injury | Injury, Brain, TraumaticUnited States
-
More FoundationElMindA Ltd; Riddell, LLC; Mimic SystemsUnknownAthletic Injuries | Concussion, BrainUnited States
-
Bayside HealthVictorian Trauma FoundationCompletedTraumatic Brain Injury | Multiple Trauma | Spinal InjuriesAustralia
-
La Trobe UniversityRecruitingAnterior Cruciate Ligament Injuries | Concussion, Brain | Musculoskeletal InjuryAustralia
-
Association de Recherche Bibliographique pour les...University of Cambridge; Centre Hospitalier Princesse Grace; Institut National...CompletedBrain Injuries | Sport Injury | Concussion, BrainMonaco
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
Clinical Trials on Genotropin (PN-180,307) Somatropin
-
PfizerCompletedInfant, Small for Gestational AgeCzech Republic, Spain, Sweden, Netherlands, Belgium, France, Germany, Italy, Switzerland
-
PfizerCompletedSmall for Gestational Age (SGA)
-
PfizerCompletedShort Stature Born Small for Gestational Age (SGA)Japan
-
PfizerCompletedSmall for Gestational Age
-
University of Erlangen-Nürnberg Medical SchoolCompletedIdiopathic Short StatureGermany
-
The University of Texas Medical Branch, GalvestonCompletedCOVID-19 | Fatigue | Cognitive Impairment | Traumatic Brain InjuryUnited States
-
Joe SpringerCompletedTraumatic Brain InjuryUnited States
-
Massachusetts General HospitalCompletedGrowth Hormone DeficiencyUnited States
-
OPKO Health, Inc.CompletedSafety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPediatric Growth Hormone DeficiencyGreece, Hungary, Slovakia
-
OPKO Health, Inc.Active, not recruitingSafety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPediatric Growth Hormone DeficiencyIsrael, United States, India, Korea, Republic of, Australia, Taiwan, Spain, Argentina, Belarus, Bulgaria, Canada, Colombia, Georgia, Greece, Mexico, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom